102 related articles for article (PubMed ID: 29534146)
1. PKC inhibition of sotrastaurin has antitumor activity in diffuse large B-cell lymphoma via regulating the expression of MCT-1.
Chang G; Zheng J; Xiao W; Chang S; Wei Q; Wu H; Tao Y; Yang G; Xie B; Lan X; Wang Y; Yu D; Hu L; Xie Y; Bu W; Kong Y; Dai B; Hou J; Shi J
Acta Biochim Biophys Sin (Shanghai); 2018 Apr; 50(4):399-407. PubMed ID: 29534146
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
Naylor TL; Tang H; Ratsch BA; Enns A; Loo A; Chen L; Lenz P; Waters NJ; Schuler W; Dörken B; Yao YM; Warmuth M; Lenz G; Stegmeier F
Cancer Res; 2011 Apr; 71(7):2643-53. PubMed ID: 21324920
[TBL] [Abstract][Full Text] [Related]
3. Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma.
Dai B; Zhao XF; Hagner P; Shapiro P; Mazan-Mamczarz K; Zhao S; Natkunam Y; Gartenhaus RB
Cancer Res; 2009 Oct; 69(19):7835-43. PubMed ID: 19789340
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage.
Nandi S; Reinert LS; Hachem A; Mazan-Mamczarz K; Hagner P; He H; Gartenhaus RB
Oncogene; 2007 Apr; 26(16):2283-9. PubMed ID: 17016429
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma.
Su Y; Sun B; Lin X; Zhao X; Ji W; He M; Qian H; Song X; Yang J; Wang J; Chen J
Oncotarget; 2016 Aug; 7(31):49143-49155. PubMed ID: 27172795
[TBL] [Abstract][Full Text] [Related]
6. DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.
Sun X; Li B; Xie B; Xu Z; Chang G; Tao Y; Zhang Y; Chang S; Wang Y; Yu D; Xie Y; Li T; Wang H; Chen G; Hu L; Hou J; Zhang Y; Xiao W; Gao L; Shi J; Zhu W
Cell Death Dis; 2017 Oct; 8(10):e3111. PubMed ID: 29022919
[TBL] [Abstract][Full Text] [Related]
7. Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.
Strömberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
Med Oncol; 2015 Jul; 32(7):188. PubMed ID: 26021470
[TBL] [Abstract][Full Text] [Related]
8. Suppression of CD300A inhibits the growth of diffuse large B-cell lymphoma.
Jiang L; Xu Y; Zeng X; Fang J; Morse HC; Zhou JX
Oncotarget; 2015 Oct; 6(31):31191-202. PubMed ID: 26435477
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
[TBL] [Abstract][Full Text] [Related]
10. The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virus.
von Hahn T; Schulze A; Chicano Wust I; Heidrich B; Becker T; Steinmann E; Helfritz FA; Rohrmann K; Urban S; Manns MP; Pietschmann T; Ciesek S
PLoS One; 2011; 6(9):e24142. PubMed ID: 21909416
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.
Lv X; Feng L; Ge X; Lu K; Wang X
J Exp Clin Cancer Res; 2016 Jul; 35(1):106. PubMed ID: 27364124
[TBL] [Abstract][Full Text] [Related]
13. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
[TBL] [Abstract][Full Text] [Related]
14. PMA/IONO affects diffuse large B-cell lymphoma cell growth through upregulation of A20 expression.
Yang W; Li Y; Li P; Wang L
Oncol Rep; 2016 Aug; 36(2):1069-75. PubMed ID: 27349720
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase C delta inhibits Caco-2 cell proliferation by selective changes in cell cycle and cell death regulators.
Cerda SR; Mustafi R; Little H; Cohen G; Khare S; Moore C; Majumder P; Bissonnette M
Oncogene; 2006 May; 25(22):3123-38. PubMed ID: 16434969
[TBL] [Abstract][Full Text] [Related]
16. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.
Pham LV; Bryant JL; Mendez R; Chen J; Tamayo AT; Xu-Monette ZY; Young KH; Manyam GC; Yang D; Medeiros LJ; Ford RJ
Oncotarget; 2016 Dec; 7(49):80599-80611. PubMed ID: 27716624
[TBL] [Abstract][Full Text] [Related]
17. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
18. A novel benzoxazinone derivative YLT-LL-11 inhibits diffuse large B-cell lymphoma growth via inducing cell cycle arrest and apoptosis.
Peng C; Sun C; Wang N; He Y; Xu J; Deng Y; Gao L; Zhong J; Xiong X; Liu L
Biosci Rep; 2019 Oct; 39(10):. PubMed ID: 31527063
[TBL] [Abstract][Full Text] [Related]
19. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.
Chen D; Mao C; Zhou Y; Su Y; Liu S; Qi WQ
Int J Oncol; 2016 Jan; 48(1):253-60. PubMed ID: 26549638
[TBL] [Abstract][Full Text] [Related]
20. [Effects of 2-12alkyl-6-methoxycyclohexa-2, 5-diene-1, 4-dione(DMDD)on diffuse large B lymphoma and its mechanism].
Hong K; Jiang PR; Ke RJ; Ying JH; Zhang XY; Chen JY
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2019 Jul; 35(4):312-316. PubMed ID: 31701713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
